Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer

Partner | Cancer Centers | <b>Weill Cornell Sandra & Edward Meyer Cancer Center</b>

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Scott Tagawa, MD, MS, FACP, a professor of medicine and urology, and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medical College, and an attending physician at New York Presbyterian Hospital, discuss the integration of targeted agents in prostate cancer.

Prostate-specific membrane antigen (PSMA)–targeted agents continue to be an area of interest following the first imaging agent approved for patients, Tagawa says. When looking at the retrospective and prospective non-randomized and randomized data, PSMA-directed therapy seems to be safe across patients, although some adverse events of interest have been observed, Tagawa explains.

However, the next phase 3 trial examining the use of these imaging agents is expected to be positive, and should lead to more FDA approvals, Tagawa continues. Additional research is needed to improve upon available options, as well as to further refine patient selection, Tagawa concludes.